|
- Ruxolitinib - Wikipedia
In the European Union, ruxolitinib cream is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age
- Ruxolitinib: Uses, Dosage, Side Effects Warnings - Drugs. com
Ruxolitinib (oral) is used to treat certain types of myelofibrosis (MF), polycythemia vera (PV), and graft-versus-host disease The brand name is Jakafi, and it is an oral tablet that is taken twice a day
- Ruxolitinib (oral route) - Side effects dosage - Mayo Clinic
Ruxolitinib is used to treat intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis
- Ruxolitinib (Jakafi): Uses Side Effects - Cleveland Clinic
Ruxolitinib is a medication that stops proteins in cells from growing It treats myelofibrosis, polycythemia vera and graft-versus-host disease
- Jakafi (ruxolitinib) - Uses, Side Effects, and More - WebMD
Jakafi (ruxolitinib) is commonly used to treat certain types of blood cancers, including myelofibrosis (MF) and polycythemia vera It is also used to treat graft versus host disease (GVHD)
- Ruxolitinib: MedlinePlus Drug Information
Ruxolitinib is in a class of medications called kinase inhibitors It works to treat myelofibrosis and PV by blocking the signals that cause cancer cells to multiply
- JAKAFI (Ruxolitinib) Label - Food and Drug Administration
Ruxolitinib is the predominant entity in humans representing approximately 60% of the drug-related material in circulation Two major and active metabolites were identified in plasma of healthy
|
|
|